177 related articles for article (PubMed ID: 27039807)
1. Pharmacological Analysis of Vorinostat Analogues as Potential Anti-tumor Agents Targeting Human Histone Deacetylases: an Epigenetic Treatment Stratagem for Cancers.
Praseetha S; Bandaru S; Nayarisseri A; Sureshkumar S
Asian Pac J Cancer Prev; 2016; 17(3):1571-6. PubMed ID: 27039807
[TBL] [Abstract][Full Text] [Related]
2. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
3. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
[TBL] [Abstract][Full Text] [Related]
4. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
8. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
9. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
11. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
12. Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
Cincinelli R; Zwick V; Musso L; Zuco V; De Cesare M; Zunino F; Simoes-Pires C; Nurisso A; Giannini G; Cuendet M; Dallavalle S
Eur J Med Chem; 2016 Apr; 112():99-105. PubMed ID: 26890116
[TBL] [Abstract][Full Text] [Related]
13. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
15. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
Sun Q; Yao Y; Liu C; Li H; Yao H; Xue X; Liu J; Tu Z; Jiang S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3295-9. PubMed ID: 23601706
[TBL] [Abstract][Full Text] [Related]
17. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
18. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
19. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
20. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]